Proficio Capital Partners LLC Acquires 144,099 Shares of Moderna, Inc. (NASDAQ:MRNA)

Proficio Capital Partners LLC lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 4,418.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 147,360 shares of the company’s stock after purchasing an additional 144,099 shares during the quarter. Proficio Capital Partners LLC’s holdings in Moderna were worth $6,127,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Knuff & Co LLC grew its position in Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after buying an additional 244 shares in the last quarter. Stephens Inc. AR grew its holdings in shares of Moderna by 7.9% during the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after purchasing an additional 245 shares in the last quarter. Allworth Financial LP increased its position in shares of Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after purchasing an additional 281 shares during the period. Howard Capital Management Inc. raised its stake in Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock valued at $416,000 after purchasing an additional 297 shares in the last quarter. Finally, Larson Financial Group LLC lifted its position in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have commented on MRNA. JPMorgan Chase & Co. set a $45.00 target price on shares of Moderna in a report on Friday, February 14th. Morgan Stanley decreased their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research report on Friday, February 14th. Berenberg Bank raised their target price on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Finally, Wolfe Research initiated coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $30.27 on Tuesday. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The business’s 50-day moving average is $37.12 and its 200-day moving average is $50.28. The company has a market capitalization of $11.68 billion, a price-to-earnings ratio of -3.26 and a beta of 1.59.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.